Form 4: Akebia CFO Sells Shares for Tax Obligations

Akebia Therapeutics' SVP, CFO, CBO & Treasurer, Erik Ostrowski, sold 34,951 shares of common stock at $1.39 per share to cover tax withholding obligations related to vested restricted stock units.

Summary

• Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, Inc. (AKBA), reported a sale of common stock.
• The transaction involved the disposition of 34,951 shares of common stock.
• The shares were sold at a price of $1.39 per share.
• The sale occurred on February 2, 2026.
• Following this transaction, Erik Ostrowski beneficially owns 672,635 shares of common stock.
• The sale was executed automatically by the Issuer to cover tax withholding obligations associated with the vesting and settlement of one-third of restricted stock units granted on January 31, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ostrowski on September 8, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a non-discretionary, tax-related transaction, which is a common occurrence for executives receiving equity compensation and does not reflect a change in management's confidence in the company's prospects.

Negatives

• A reduction in direct insider ownership by 34,951 shares, although for tax purposes, slightly decreases management's direct equity stake.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that sales of company stock by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine practice across various industries, particularly in biotechnology and pharmaceuticals where equity compensation is a significant component of executive pay.

Comparison to Industry Standards

• This type of transaction, a 'sell-to-cover' for tax obligations, is a standard mechanism for executives to manage tax liabilities arising from equity compensation. It is widely observed among publicly traded companies, including peers of Akebia Therapeutics in the biotechnology sector, such as Biogen Inc. (BIIB) or Vertex Pharmaceuticals Inc. (VRTX), where executives frequently report similar transactions upon RSU vesting.

Related Party Transactions

• The transaction involves an insider (Erik Ostrowski) selling shares of the issuer (Akebia Therapeutics, Inc.), which is a form of related party dealing in the context of insider trading regulations.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but generally considered a routine event with minimal impact on shareholder sentiment given the tax-related nature of the sale.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale by an executive to cover tax obligations associated with vested equity awards, executed under a pre-established 10b5-1 plan. This type of insider activity typically does not signal a change in the company's fundamental outlook or management's confidence, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Akebia Therapeutics, AKBA, Erik Ostrowski, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, 10b5-1 Plan